The U.S. Supreme Court recently issued its decision in Amgen Inc. v. Sanofi; a decision long-awaited by patent practitioners. In its decision, the Court unanimously held that several of Amgen’s patent claims to a class of antibodies were invalid for lack of enablement.
Under U.S. law, patent marking is optional. One may ask, well, then why do it? The short answer; damages.
If your client’s invention is focused on, or relates to, achieving net-zero greenhouse gas emissions, the U.S. Patent and Trademark Office (USPTO) is in your corner, now more than ever. On June 6, 2023, the USPTO expanded the eligibility requirements of the Climate Change Mitigation Pilot Program to apply to a greater breadth of technologies.
In April 2023, the U.S. Patent & Trademark Office (USPTO) announced proposed changes to some of the fees that it charges with respect to patent applications, design patents and America Invents Act trials.
- EventHealthcare and FDA Compliance in 2025: Litigation Insights & Real-World Strategies
- EventHealth Law Webinar – The Most Common Questions and Misconceptions About Audits and Reviews
- EventHow to Prepare for Immigration Enforcement at Your Worksite and in Your Community
- Firm NewsFredrikson Expands Corporate and Tax Practices with Iowa Hires